Endothelin, endothelin receptors, and endothelin antagonists
- PMID: 7850417
Endothelin, endothelin receptors, and endothelin antagonists
Abstract
Endothelin is a peptide with potent biologic effects in vascular and nonvascular cells. Its effects are mediated by two receptors, ETA and ETB, and possibly also by a third receptor, ETC. In vascular smooth muscle cells, endothelin causes profound contraction and also has proliferative effects, mainly through activation of ETA but also through ETB receptors. Activation of endothelin receptors on vascular smooth muscle explains the profound vasoconstriction observed in isolated blood vessels as well as with infusion of the peptide in vivo. Endothelial cells can express ETB receptors linked to the formation of nitric oxide or prostacyclin. Activation of these receptors leads to the transient vasodilation observed with intravascular infusion of the peptide. In vascular smooth muscle, activation of endothelin receptors stimulates phospholipase C, with concomitant formation of inositol triphosphate and diacylglycerol. These events lead to the release of intracellular calcium and initiation of contraction. In addition, endothelin can activate voltage-operated calcium channels via Gi proteins, thereby increasing influx of extracellular calcium. The later phenomenon may explain the ability of calcium antagonists to inhibit endothelin-induced contractions. Normally, circulating endothelin levels, as well as production of the peptide in isolated blood vessels, are rather low due to the absence of stimuli and the presence of potent inhibitory mechanisms. Important stimulators of endothelin production are thrombin, angiotensin II, arginine vasopressin, and transforming growth factor-beta, as well as certain cytokines and physicochemical factors such as hypoxia.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Endothelin-induced vasoconstriction and calcium antagonists.J Hum Hypertens. 1992 Dec;6 Suppl 2:S3-8. J Hum Hypertens. 1992. PMID: 1289511 Review.
-
Endothelin.J Cardiovasc Pharmacol. 1991;18 Suppl 10:S15-22. J Cardiovasc Pharmacol. 1991. PMID: 1724999 Review.
-
Endothelin and endothelin antagonists: pharmacology and clinical implications.Agents Actions Suppl. 1995;45:237-53. doi: 10.1007/978-3-0348-7346-8_34. Agents Actions Suppl. 1995. PMID: 7717186 Review.
-
Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biologic properties.Am Rev Respir Dis. 1992 Nov;146(5 Pt 2):S56-60. doi: 10.1164/ajrccm/146.5_Pt_2.S56. Am Rev Respir Dis. 1992. PMID: 1332560 Review.
-
Effects of peptide vasoconstrictors on vessel structure.Am J Med. 1993 Apr 23;94(4A):13S-19S. Am J Med. 1993. PMID: 8488851 Review.
Cited by
-
Defining cell populations with single-cell gene expression profiling: correlations and identification of astrocyte subpopulations.Nucleic Acids Res. 2011 Mar;39(4):e24. doi: 10.1093/nar/gkq1182. Epub 2010 Nov 25. Nucleic Acids Res. 2011. PMID: 21112872 Free PMC article.
-
ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo.Am J Physiol Renal Physiol. 2008 Aug;295(2):F360-8. doi: 10.1152/ajprenal.00512.2007. Epub 2008 Jun 4. Am J Physiol Renal Physiol. 2008. PMID: 18524860 Free PMC article.
-
Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension.Ann Rheum Dis. 1995 Sep;54(9):730-4. doi: 10.1136/ard.54.9.730. Ann Rheum Dis. 1995. PMID: 7495344 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources